Takeda Pharmaceutical Company has announced a significant global collaboration and license agreement with Halozyme Therapeutics, focusing on the integration of Halozyme’s proprietary ENHANZE drug delivery technology with Takeda’s vedolizumab.
This strategic partnership aims to improve patient care and explore new therapeutic avenues for vedolizumab, a treatment for moderately to severely active ulcerative colitis and Crohn’s disease. The collaboration involves upfront payments, milestone payments, and royalties for Halozyme, underscoring the shared commitment to advancing inflammatory bowel disease (IBD) management.
Key Takeaways
- Takeda and Halozyme enter a global agreement to utilize ENHANZE technology with vedolizumab.
- The partnership seeks to enhance patient experience and expand treatment options for IBD.
- ENHANZE technology facilitates subcutaneous drug delivery, potentially reducing treatment time for patients.
- Financial terms include upfront, milestone, and royalty payments to Halozyme.
Advancing Inflammatory Bowel Disease Treatment
Vedolizumab, marketed as Entyvio, is a crucial therapy for individuals managing chronic and complex inflammatory bowel diseases like ulcerative colitis and Crohn’s disease. These conditions often require evolving treatment strategies over time.
By incorporating Halozyme’s ENHANZE technology, Takeda intends to offer a more convenient subcutaneous delivery option for vedolizumab. This approach leverages Halozyme’s proven recombinant human hyaluronidase PH20 (rHuPH20) enzyme, which has a successful track record in over ten commercialized products reaching more than a million patients globally.
Enhancing Patient Experience and Therapeutic Value
Robert Hollowell, Takeda’s Global Product and Launch Strategy, GI and Inflammation Head, emphasized the long-standing role of vedolizumab in patient management and highlighted the collaboration as a testament to Takeda’s dedication to the IBD community and its pursuit of innovative research.
Dr. Helen Torley, President and CEO of Halozyme, expressed enthusiasm for the partnership, stating that ENHANZE’s ability to facilitate subcutaneous drug delivery can help patients dedicate less time to therapy and more to living their lives. She also noted the broad applicability and value of ENHANZE across various therapeutic areas.
This agreement builds upon Takeda’s ongoing efforts to innovate in the IBD space, including a recent research collaboration with Nabla Bio focused on AI-driven protein therapeutic design.
Sources
Founder Dinis Guarda
IntelligentHQ Your New Business Network.
IntelligentHQ is a Business network and an expert source for finance, capital markets and intelligence for thousands of global business professionals, startups, and companies.
We exist at the point of intersection between technology, social media, finance and innovation.
IntelligentHQ leverages innovation and scale of social digital technology, analytics, news, and distribution to create an unparalleled, full digital medium and social business networks spectrum.
IntelligentHQ is working hard, to become a trusted, and indispensable source of business news and analytics, within financial services and its associated supply chains and ecosystems
